The health and safety of our employees, patients, customers and communities is our top priority. Read about our response to COVID-19

Inspire Medical Systems Announces FDA Approval of Inspire 3028 Neurostimulator for the Treatment of Obstructive Sleep Apnea

Download as PDF

Next generation technology is 40% smaller & 18% thinner than
current neurostimulator and includes MRI Conditional labeling
Product launched at SLEEP 2017 annual meeting, taking place in Boston June 3-7

MINNEAPOLIS (June 5, 2017) — Inspire Medical Systems, Inc., manufacturer of the
only FDA-approved implantable device for obstructive sleep apnea (OSA), has received
U.S. Food and Drug Administration (FDA) approval for its next-generation device, the
Inspire 3028 implantable pulse generator, which includes magnetic resonance (MR)
conditional labeling, allowing patients to undergo magnetic resonance imaging (MRI)

“The continuous positive airway pressure (CPAP) intolerant patients I see want to lead
active and engaging lives,” said Alan Kominsky, MD, a practicing ENT-otolaryngologist
at the Cleveland Clinic. “With conditional MRI labeling, the new Inspire device provides
my OSA patients peace of mind now that MRIs are an option. Similar to approvals in the
cardiac and neurological implantable device arenas, this labeling expansion is a welcome
addition to the upper airway stimulation therapy.”

In addition to the conditional MRI labeling, the newly approved implantable device
provides many OSA patients with a size profile that meets the needs of patients who
cannot use or get benefit from CPAP. The Inspire 3028 device is 40% smaller and 18%
thinner than the current Inspire neurostimulator which received FDA approval in April

“We have received consistent feedback from the medical community that providing the
ability for patients to have an MRI is very important,” said Tim Herbert, President and
CEO of Inspire Medical Systems. “We incorporated features to allow for an MRI and
redesigned the device to have both a smaller footprint as well as being significantly
thinner without compromising product functionality or device battery life which remains
at about 11 years. We believe that the peace of mind and improved patient comfort with
this next generation device will have a direct and positive impact on the commercial
opportunity for Inspire therapy.”

Inspire therapy is currently being implanted in over 100 leading medical centers across
the United States and over 25 centers in Europe. Over 1,700 patients worldwide are
currently using Inspire therapy, and objective and subjective patient outcomes have
proven the therapeutic benefit of the technology.

Inspire also announced that two key publications have been issued in peer-reviewed
medical journals further describing the safety and efficacy of Inspire therapy. First, the
four-year long-term follow-up clinical data of patients in the STAR phase III pivotal trial
was published in the journal, Otolaryngology–Head and Neck Surgery, in May 2017.
The results of the four-year follow-up showed sustained quality of life improvements in
patients who have used the therapy for over four years.

Also published, in the April 2017 of Otolaryngology–Head and Neck Surgery, was the
first multi-center trial conducted to validate the results of the STAR trial. This second
trial was conducted in Germany with 60 patients implanted with the Inspire device. The
authors concluded that selective upper airway stimulation is a safe and effective therapy
for patients with obstructive sleep apnea and represents a powerful option for its surgical

“Inspire therapy is proving to be a valuable option for patients who are unable to tolerate
CPAP,” said Kingman Strohl, MD, Professor of Medicine at Case Western Reserve
University School of Medicine and Program Director, Sleep Medicine at UH Cleveland
Medical Center. “I remain convinced that we will continue to see outstanding patient
outcomes with the Inspire therapy system and am confident this next generation of
smaller and thinner device with conditional MRI labeling will be an important therapy for
my untreated OSA patients.”

Inspire will be announcing the approval of the Inspire 3028 neurostimulator at SLEEP
2017, the joint meeting of the American Academy of Sleep Medicine and the Sleep
Research Society, June 3rd – 7th in Boston. Further, several physicians who have
investigated the safety and efficacy of Inspire therapy will present their results during this
meeting including the 5-year long-term clinical data from the STAR phase III pivotal as
well as additional independent clinical trials and reporting on long-term compliance to
the therapy. On Monday, June 5, 2017 at 12:45pm ET, Inspire is sponsoring an Industry
Product Theater titled, “Incorporating Inspire Upper Airway Stimulation into Your

About Inspire Therapy
Inspire Upper Airway Stimulation therapy is an FDA-approved treatment for some
people with moderate to severe Obstructive Sleep Apnea who are unable to use or get
consistent benefit from continuous positive airway pressure (CPAP). In contrast to
CPAP, Inspire therapy is implanted inside the body and works with a patient’s natural
breathing process. Controlled by the small handheld sleep remote, the system includes a
breathing sensor and a stimulation lead powered by a small battery. During sleep, the
system senses breathing patterns and delivers mild stimulation to the tongue and other
soft tissues of the throat to keep the airway open. Inspire therapy is currently available at
more than 100 leading medical centers across the United States and Europe.

About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc., based in Minneapolis, Minn., was incorporated with the
purpose of developing a safe, effective and well-accepted therapy to help those OSA
patients who are unable to tolerate or get relief from CPAP. Inspire therapy is the world’s
first implantable FDA-approved neurostimulation system for the treatment of OSA. The
Company is privately held and investors include Amzak Health, Aperture Venture
Partners, GDN Holdings, Johnson & Johnson, Kleiner Perkins Caufield & Byers,
Medtronic, OrbiMed Advisors, Synergy Life Science Partners, TGap Ventures and US
Venture Partners.

For more information, visit

Investor Contact:
Rick Buchholz
[email protected]

Media Contact:
Howard Green
[email protected]